Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR2 | Q9NS75 | 5/20 | 0.50 |
| ▸ | CYSLTR1 | Q9Y271 | 5/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.44 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.42 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15245051 | 0.87 | CYSLTR2 (0.55) | CYSLTR2CYSLTR1SMN1; SMN2KMT2AKDM4E | |
| SCHEMBL16805947 | 0.85 | LMNA (0.54) | SMN1; SMN2KMT2AKDM4EALDH1A1LMNA | |
| SCHEMBL16805950 | 0.84 | L3MBTL1 (0.46) | ALDH1A1FFAR4FFAR1HPGD | |
| SCHEMBL20231598 | 0.84 | KDM4E (0.65) | CYSLTR2CYSLTR1SMN1; SMN2KMT2AKDM4E | |
| SCHEMBL20231599 | 0.79 | KDM4E (0.66) | CYSLTR2CYSLTR1SMN1; SMN2KMT2AKDM4E | |
| SCHEMBL20231594 | 0.79 | KDM4E (0.66) | CYSLTR2CYSLTR1SMN1; SMN2KMT2AKDM4E | |
| SCHEMBL24675410 | 0.78 | CYSLTR2 (0.54) | CYSLTR2CYSLTR1SMN1; SMN2KMT2AKDM4E | |
| SCHEMBL24675791 | 0.78 | CYSLTR2 (0.54) | CYSLTR2CYSLTR1SMN1; SMN2KMT2AKDM4E | |
| SCHEMBL24675411 | 0.78 | CYSLTR2 (0.54) | CYSLTR2CYSLTR1SMN1; SMN2KMT2AKDM4E | |
| SCHEMBL24675240 | 0.75 | CYSLTR2 (0.54) | CYSLTR2CYSLTR1SMN1; SMN2KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9481684-B2 | Gonadotropin releasing hormone receptor antagonists, method for the preparation thereof and pharmaceutical composition comprising the same | SK CHEMICALS CO., LTD. (KR) | 2016-11-01 | — | — | US | disclosed |
| US-20150166558-A1 | GONADOTROPIN RELEASING HORMONE RECEPTOR ANTAGONISTS, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | SK CHEMICALS CO., LTD. (KR) | 2015-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150166558-A1 | GONADOTROPIN RELEASING HORMONE RECEPTOR ANTAGONISTS, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | GNRHR, FSHR, GHRHR | CYSLTR2 1084/4885CYSLTR1 919/4885SMN1; SMN2 1582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.